Introduction {#s1}
============

Due to the introduction of low-dose computed tomography (CT) and screening procedures, the number of diagnoses of pulmonary ground glass opacity (GGO) lung cancer in clinical practice is increasing ([@B1], [@B2]). The GGO manifestation is generally caused by local airspace filling as a result of inflammation or neoplastic proliferation, and some studies reported that the malignancy rate of GGO was 63%, which has a higher malignant potential than solid nodules ([@B3], [@B4]). The GGO manifestation generally correlates with a lepidic, *in situ*, non-invasive growth pattern of cells along preexisting alveolar structures ([@B4]). A previous study has reported that GGO lung cancer may have several unique features, including an insignificant association with smoking history and a low degree of invasive biological characteristics ([@B3]). As the importance of GGO lung cancer is increasing, more researches have focused on the diagnosis and treatment of this early stage lung cancer; however, the epidemiology of lung cancer with GGO manifestation has not yet been fully elucidated. In this study, we summarized all of the publications concerning solitary GGO adenocarcinoma lung cancer (ADLC) and investigated the epidemiological data of this unique type of lung cancer by the use of a cumulative meta-analysis. The primary outcome is female proportion, and the secondary outcomes are average diagnosis age and non-smoking proportion. All analyses of our study were specified *a priori* in the protocol, and our study was registered and the protocol made available on the PROSPERO (the registration number CRD42019119240).

Methods {#s2}
=======

This study was reported on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines ([Supplementary Table 1](#SM4){ref-type="supplementary-material"}).

Two individual researchers conducted the platform searches on the PubMed, Cochrane Library, and Embase databases. Literature retrieving was carried out through a combined searching of subject terms ("MeSH" on PubMed and "Emtree" on "Embase") and free terms on the platforms of PubMed and Embase, and through keywords searching on platform of Cochrane Library. Detailed searching criteria used in the three electronic platforms are available in [Appendix 1](#SM5){ref-type="supplementary-material"}.

All available studies that had been published in English until January 1, 2019 on patients with solitary GGO ADLC were included, and the inclusion and exclusion criteria were listed. The inclusion criteria of study were (1) GGO manifestation and (2) finally pathologically confirmed ADLC. The exclusion criteria were the following: (1) studies with a design of literature review, systematic review, basic research, letter to editors, diagnostic study, and so on; (2) studies that include the following cases and cannot be ruled out---multiple GGO, benign GGO, or pure solid nodules; (3) studies that did not involve basic information of patients; and (4) studies using repeated patients cohorts with any other study. There were no limitations on the participants\' nationalities.

The Newcastle--Ottawa quality assessment scale (NOS) and National Institute for Clinical Excellence (NICE) quality assessment scale were performed to assess methodological quality and risk of bias for cohort studies and case series studies, respectively. We extracted the general characteristics of GGO patients (amount, age, gender, and smoking status) to perform the meta-analysis. For the proportions of GGO adenocarcinoma of the female gender and the smoking histories, the single rate was determined, and the single mean value was used for the calculation of the average diagnosis ages of the patients. Meta-analysis was performed on all the data using fixed or random effect through heterogeneity, which was tested by estimating value of *I*^2^ (significance level at *I*^2^ \> 50%) or using the Cochrane *Q*-test (significance level at *P* \< 0.100). The cumulative meta-analysis was also performed, and the trend test was performed to confirm the trend of cumulative meta-analysis, as sorted by years. The methods of Begg\'s and Egger\'s regression asymmetry test were performed to test publication bias, and *P* \< 0.050 and *P* \< 0.100 were considered to be statistically significant publication bias for Begg\'s and Egger\'s, respectively, ([@B5]). If the *P*-value indicates the existence of publication bias, the non-parametric trim and fill method would be performed to revise the result of meta-analysis ([@B6]). Sensitivity analysis was performed by omitting each individual study to check the stability of the result, and studies causing instability would be removed from the meta-analysis. The whole process of data analyses was performed by the software Stata version 13.0 (Stata Corp LLC, College Station, TX, USA).

Results {#s3}
=======

The process of eligible literature selection is presented in [Figure 1](#F1){ref-type="fig"}, and a total of 8,793 solitary GGO ADLC patients from 53 studies until 2019 were recruited in the meta-analysis, mainly focusing on age, gender, and smoking status ([@B7]--[@B59]). No article was excluded by methodological quality and risk of bias and sensitivity analysis for significant heterogeneity ([Supplementary Figures 1](#SM1){ref-type="supplementary-material"}--[3](#SM3){ref-type="supplementary-material"}). The summary of individual study is listed in [Table 1](#T1){ref-type="table"}. All the meta-analyses were performed with a random-effect model (*I*^2^ \> 50%).

![Flowchart of studies identification and selection.](fonc-10-01059-g0001){#F1}

###### 

Summary of included studies.

  **Author**                  **Character of studies**   **Character of patients**                                                                            
  --------------------------- -------------------------- --------------------------- ------- --- --------------------- ----- ----------------- ------ ------- ------
  Kodama et al. ([@B59])      2001                       Retrospective cohort        Japan   7   Lung adenocarcinoma   52    0 \< *R* ≤ 1      0.52   NA      NA
  Matsuguma et al. ([@B58])   2002                       Retrospective cohort        Japan   7   Lung adenocarcinoma   57    0 \< *R* ≤ 1      0.68   NA      0.65
  Suzuki et al. ([@B57])      2002                       Case series                 Japan   5   Lung adenocarcinoma   69    0 \< *R* ≤ 1      0.55   NA      NA
  Nakamura et al. ([@B56])    2004                       Case series                 Japan   6   Lung adenocarcinoma   27    *R* = 1           0.56   66.40   NA
  Nakata et al. ([@B55])      2005                       Retrospective cohort        Japan   8   Lung adenocarcinoma   101   10 ≤ *R* ≤ 1      0.60   62.76   0.37
  Suzuki et al. ([@B54])      2006                       Case series                 Japan   5   Lung adenocarcinoma   170   0 \< *R* ≤ 1      0.60   NA      NA
  Park et al. ([@B53])        2009                       Case series                 Korea   5   Lung adenocarcinoma   44    *R* = 1           0.50   NA      NA
  Okada et al. ([@B52])       2011                       Retrospective cohort        Japan   8   Lung adenocarcinoma   304   20 ≤ *R* ≤ 1      0.61   65.00   NA
  Cho et al. ([@B51])         2013                       Case series                 Korea   5   Lung adenocarcinoma   28    *R* = 1           0.32   NA      NA
  Duann et al. ([@B50])       2013                       Retrospective cohort        China   6   Lung adenocarcinoma   46    50 ≤ *R* ≤ 1      0.50   60.28   NA
  Lim et al. ([@B49])         2013                       Case series                 Korea   5   Lung adenocarcinoma   46    *R* = 1           0.43   NA      0.70
  Tsutani et al. ([@B48])     2013                       Retrospective cohort        Japan   8   Lung adenocarcinoma   299   0 \< *R* \< 1     0.57   65.70   NA
  Uehara et al. ([@B47])      2013                       Retrospective cohort        Japan   8   Lung adenocarcinoma   334   25 ≤ *R* ≤ 1      0.61   65.40   NA
  Hattori et al. ([@B46])     2014                       Case series                 Japan   5   Lung adenocarcinoma   112   0 \< *R* \< 1     0.63   NA      NA
  Tsutani et al. ([@B45])     2014                       Retrospective cohort        Japan   7   Lung adenocarcinoma   239   50 \< *R* ≤ 1     0.61   NA      NA
  Zhang et al. ([@B44])       2014                       Case series                 China   5   Lung adenocarcinoma   43    50 ≤ *R* ≤ 1      0.79   NA      NA
  Cho et al. ([@B43])         2015                       Retrospective cohort        Korea   8   Lung adenocarcinoma   164   *R* = 1           0.55   61.50   0.65
  Cho et al. ([@B42])         2015                       Retrospective cohort        Korea   7   Lung adenocarcinoma   71    0.25 \< *R* ≤ 1   0.59   NA      NA
  Hwang et al. ([@B41])       2015                       Retrospective cohort        Korea   8   Lung adenocarcinoma   197   0 \< *R* ≤ 1      0.61   61.32   NA
  Nakamura ([@B40])           2015                       retrospective cohort        Japan   7   Lung adenocarcinoma   25    50 ≤ *R* ≤ 1      0.52   NA      NA
  Sakurai et al. ([@B39])     2015                       Retrospective cohort        Japan   8   Lung adenocarcinoma   201   0 \< *R* ≤ 1      0.57   NA      0.56
  Yang et al. ([@B38])        2015                       Retrospective cohort        China   6   Lung adenocarcinoma   158   0 \< *R* ≤ 1      0.61   56.07   0.76
  Choi et al. ([@B37])        2016                       Retrospective cohort        Korea   8   Lung adenocarcinoma   288   0.2 \< *R* ≤ 1    0.56   59.30   0.68
  Hattori et al. ([@B36])     2016                       Retrospective cohort        Japan   8   Lung adenocarcinoma   616   0 \< *R* \< 1     0.62   66.60   NA
  Moon et al. ([@B35])        2016                       Retrospective cohort        Korea   8   Lung adenocarcinoma   83    *R* = 1           0.63   NA      0.77
  Qiu et al. ([@B34])         2016                       Case series                 China   5   Lung adenocarcinoma   81    0 \< *R* ≤ 1      0.68   NA      0.79
  Si et al. ([@B33])          2016                       Retrospective cohort        China   6   Lung adenocarcinoma   53    *R* = 1           0.85   NA      0.89
  Fukui et al. ([@B32])       2017                       Retrospective cohort        Japan   7   Lung adenocarcinoma   250   50 ≤ *R* ≤ 1      0.58   63.52   NA
  Hattori et al. ([@B31])     2017                       Retrospective cohort        Japan   8   Lung adenocarcinoma   177   0 \< *R* ≤ 0.5    0.63   66.70   NA
  Hattori et al. ([@B30])     2017                       Retrospective cohort        Japan   8   Lung adenocarcinoma   262   0 \< *R* ≤ 1      0.68   61.03   NA
  Moon et al. ([@B29])        2017                       Retrospective cohort        Korea   8   Lung adenocarcinoma   52    0.5 \< *R* ≤ 1    0.60   NA      0.77
  She et al. ([@B28])         2017                       Retrospective cohort        China   8   Lung adenocarcinoma   898   *R* = 1           0.65   54.12   0.90
  Wang et al. ([@B27])        2017                       Retrospective cohort        China   6   Lung adenocarcinoma   67    *R* = 1           0.81   55.81   NA
  Zhou et al. ([@B26])        2017                       Case series                 China   5   Lung adenocarcinoma   137   *R* = 1           0.78   NA      NA
  Berry et al. ([@B25])       2018                       Retrospective cohort        USA     8   Lung adenocarcinoma   69    0 \< *R* ≤ 0.25   0.62   69.00   0.46
  Huang et al. ([@B24])       2018                       Retrospective cohort        China   8   Lung adenocarcinoma   789   0 \< *R* ≤ 1      0.67   61.28   0.77
  Kim et al. ([@B23])         2018                       Retrospective cohort        Korea   8   Lung adenocarcinoma   202   0 \< *R* ≤ 1      0.50   NA      0.73
  Kim and Goo ([@B22])        2018                       Case series                 Korea   5   Lung adenocarcinoma   117   *R* = 1           0.55   NA      NA
  Lee et al. ([@B21])         2018                       Retrospective cohort        Korea   6   Lung adenocarcinoma   36    *R* = 1           0.69   NA      0.89
  Li et al. ([@B20])          2018                       Retrospective cohort        China   6   Lung adenocarcinoma   393   0 \< *R* ≤ 1      0.70   NA      0.75
  Li et al. ([@B19])          2018                       Retrospective cohort        China   6   Lung adenocarcinoma   109   0 \< *R* ≤ 1      0.68   57.21   NA
  Liu et al. ([@B18])         2018                       Case series                 China   5   Lung adenocarcinoma   48    0 \< *R* ≤ 1      0.77   NA      NA
  Predina et al. ([@B17])     2018                       Case series                 USA     5   Lung adenocarcinoma   20    0 \< *R* ≤ 1      0.65   NA      NA
  Sagawa et al. ([@B16])      2018                       Prospective cohort          Japan   7   Lung adenocarcinoma   53    0.8 ≤ *R* ≤ 1     0.53   NA      NA
  Su et al. ([@B15])          2018                       Retrospective cohort        China   8   Lung adenocarcinoma   245   0 \< *R* ≤ 1      0.64   59.33   0.78
  Suzuki et al. ([@B14])      2018                       Retrospective cohort        Japan   8   Lung adenocarcinoma   160   0 \< *R* ≤ 1      0.51   NA      0.44
  Wang et al. ([@B13])        2018                       Case series                 China   5   Lung adenocarcinoma   146   0 \< *R* \< 1     0.66   NA      0.92
  Wang et al. ([@B12])        2018                       Retrospective cohort        China   8   Lung adenocarcinoma   165   *R* = 1           0.78   54.20   NA
  Wang et al. ([@B11])        2018                       Case series                 China   6   Lung adenocarcinoma   230   0 \< *R* \< 1     0.58   NA      NA
  Xue et al. ([@B10])         2018                       Retrospective cohort        China   6   Lung adenocarcinoma   68    0 \< *R* \< 0.5   0.69   52.30   0.69
  Yagi et al. ([@B9])         2018                       Case series                 Japan   6   Lung adenocarcinoma   101   0 \< *R* ≤ 1      0.55   69.42   NA
  Yang et al. ([@B8])         2018                       Case series                 China   6   Lung adenocarcinoma   51    0 \< *R* ≤ 0.5    0.57   69.40   NA
  Yao et al. ([@B7])          2018                       Retrospective cohort        China   6   Lung adenocarcinoma   40    50% \< *R* ≤ 1    0.68   NA      0.78

*Summary of 53 studies with 8,793 patients from the literatures. Newcastle--Ottawa quality assessment scale (NOS) and National Institute for Clinical Excellence quality assessment scale (NICE) were performed to assess methodological quality and risk of bias for cohort studies and case series studies, respectively*.

For the female proportion of GGO ADLC, all 8,793 patients were included in the meta-analysis, and the results demonstrated that the female proportion was 0.62 (95% CI, 0.60--0.64), and the *P*-value of Begg\'s and Egger\'s test is \> 0.1, indicating that there was no existence of publication bias ([Figure 2](#F2){ref-type="fig"}). For average diagnosis age group, 24 articles involving 5,785 GGO ADLC patients were included for the meta-analysis of age ([Figure 3A](#F3){ref-type="fig"}). The *P*-value of Egger\'s test was 0.015, which indicated the presence of publication bias, and the non-parametric trim-and-fill method was performed to adjust the effect value ([@B5]). Eleven studies were filled to rectify bias, and the final pooled average diagnosis age was 56.97 (95% CI, 54.56--59.37) ([Figure 3C](#F3){ref-type="fig"}). A total of 4,330 GGO ADLC patients from 22 articles were assessed in the meta-analysis for smoking status ([Figure 3B](#F3){ref-type="fig"}). The *P*-value of Egger\'s test was 0.003, and the non-parametric trim-and-fill method was performed. No studies were estimated to rectify the bias, and the final pooled non-smoking proportion of solitary GGO ADLC was 0.72 (95% CI, 0.66--0.77) ([Figure 3D](#F3){ref-type="fig"}).

![The meta-analysis forest map of the female rate of solitary ground glass opacity (GGO) adenocarcinoma lung cancer (ADLC).](fonc-10-01059-g0002){#F2}

![The meta-analysis forest maps, funnel plot with non-parametric trim-and-fill method for solitary ground glass opacity (GGO) adenocarcinoma lung cancer (ADLC). **(A)** The meta-analysis forest map of the average diagnosis age; **(B)** the meta-analysis forest map of the non-smoking rate; **(C)** the funnel plot of average age group with non-parametric trim and fill method; **(D)** the funnel plot of non-smoking rate group with non-parametric trim and fill method.](fonc-10-01059-g0003){#F3}

The cumulative meta-analysis of age group demonstrated that the average age had decreased from 66.40 to 59.06 years (95% CI, 58.84--59.28) ([Figure 4A](#F4){ref-type="fig"}), and the meta-trend analysis confirmed that the decrease in age was statistically significant (*P* \< 0.001) ([Figure 4C](#F4){ref-type="fig"}). The cumulative meta-analysis of non-smoking group indicated that the non-smoking proportion in GGO patients has increased in the past two decades ([Figure 4B](#F4){ref-type="fig"}), which was statistically significant in the meta-trend analysis (*P* \< 0.001) ([Figure 4D](#F4){ref-type="fig"}).

![The cumulative meta-analysis forest maps and meta-trend analysis for solitary ground glass opacity (GGO) adenocarcinoma lung cancer (ADLC), as sorted by years. **(A)** The cumulative meta-analysis forest map of the female rate; **(B)** the cumulative meta-analysis forest map of the non-smoking rate; **(C)** the trend analysis for the cumulative meta-analysis of the female rate; **(D)** the trend analysis for the cumulative meta-analysis of the non-smoking rate.](fonc-10-01059-g0004){#F4}

Discussion {#s4}
==========

GGO-predominant lung cancers are typically characterized as non-invasively or minimally invasively low-grade adenocarcinomas and had good prognosis after surgical intervention ([@B60]). Early detection and therapeutic intervention for these early stage lung cancers is an important opportunity for decreasing overall mortality of lung cancer. Some lung cancer screening criteria have been proposed, which always consider heavy smoking history as a key factor for risk assessment ([@B61], [@B62]). The US Preventive Services Task Force (USPSTF) recommends lung cancer screening among individuals aged 55--80 years with a 30 pack-year cigarette smoking history ([@B61]). In addition, the latest Lung Cancer Screening from National Comprehensive Cancer Network (NCCN) Guidelines determines age \<50 years and smoking history lower than 20 pack-year as low risk, in which lung cancer screening is not recommended ([@B62]). Our meta-analysis indicates that the pooled non-smoking proportion is 0.72. The majority of GGO lung cancer patients are female, and the average age at diagnosis has been significantly decreasing in the past two decades. Our data demonstrate that the clinical characteristics of GGO lung cancer patients may be out of the high-risk factors who are inappropriate for the lung cancer screening. Zhang et al. performed LDCT for 8,329 hospital employees from different regions, and 179 cases were pathologically confirmed lung cancer and 98.9% (171) cases presented with GGO ([@B63]). In Zhang\'s study, there was a higher lung cancer detection rate in female than male patients (2.5 vs. 1.3%), and the lung cancer detection rate of non-smokers was also high than smokers (2.2 vs. 1.4%). In subset analysis by age, the lung cancer detection rates were 1.0, 2.6, and 2.9% in the "age ≤ 40 years," "40 \< age ≤ 55 years," and "age \> 55 years" group, respectively ([@B63]). According to this substantial data, Zhang proposed that the "high-risk" population for lung cancer is changing, and more lung cancers from the traditionally "low-risk" groups, such as young female non-smokers, could be detected by LDCT ([@B63]). These finding are completely consistent with our study. More and more female younger non-smokers were diagnosed with lung cancer; however, the exact reasons of this phenomenon are still uncertain. Most researchers thought that the phenomenon may be caused by life pressure, living habits, and hormone levels; however, it needs to be further investigated. Luo et al. conducted a cohort study that demonstrated that younger and light smoker patients with lung cancer who are not recommended for screening have similar lung cancer survival to those lung cancer patients who meet all the USPSTF screening criteria ([@B64]). This study supports our findings that the individuals with low-risk factors should be concerned as well, and the criteria of current lung cancer screening might not be perfect. However, the cost effectiveness needs to be evaluated if more low risk individuals are included in low-dose computed tomography (CT) screening ([@B65]). A limitation of this study is that all of the included studies were retrospective studies that have a lower level of evidence compared to prospective studies.

Conclusions {#s5}
===========

Our study demonstrated that the majority of GGO ADLC patients are female with non-or light smoking history, and the average age at diagnosis has been significantly decreasing. This indicates that there are more lung cancers being detected from the traditionally "low-risk" groups, such as young female non-smokers. It is well-accepted that early detection of lung cancers is the most important procedure that contributes to improved survival outcomes and reduced lung cancer mortality. Therefore, we propose that, in order to identify these very early stage GGO lung cancer patients with low-risk factors, it is necessary to reconsider the risk assessment and current lung cancer screening criteria.
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